cctex said:
Thanks for the info bbball3350! So let me get this straight. Bromo is only %54 effective on returning prolactin levels back to normal, cheaper and I assume you would take it the same way as Dostinex, but if does work, its has a greater chance of keeping prolactin levels normal in the long run?
No, Bromo and Dostinex both work well in their own ways to inhibit prolactin. But AFTER treatment only 54% of Bromo patients' prolactin levels returned to normal.
And I'm not sure about Bromos dosage. Dostinex has a very long half life, hense the weird dosage layout. I've never looked up Bromo passed much of this because i've seen the harsh gastrointestinal side effects many people.
I'm just gonna put some interesting info i've heard about the two *sorry in advanced for the unneatness*
"As compared to bromocriptine, CAB(Cabergoline/Dostinex) was more potent in inhibiting the binding of [3H]N-n-propylnorapomorphine and it occupied the receptor for longer."
"CAB at doses of 0.125-1 mg twice weekly caused a dose-dependent suppression of PRL(Prolactin) secretion in women with hyperprolactinaemia. CAB was shown to be significantly more effective than bromocriptine in inducing a complete biochemical response and clinical efficacy and was better tolerated than bromocriptine in the majority of patients."
And thats with a woman WITH hyperprolactinaemia, which is a over secretion of prolactin way more than you'll have with reasonable trenbolones and nandrolones.
"CAB was also shown to be effective in patients resistant or poorly responsive to bromocriptine."
"The affinities of cabergoline and pergolide for the D2 receptor were about the same, about 7 times stronger than that of bromocriptine. The affinity of each compound for the D1 receptor was markedly lower than its affinity for the D2 receptor. However, other data suggest that cabergoline and pergolide would have D1-receptor agonist activity, whereas bromocriptine would act as a D1-receptor antagonist."
antagonist(bromo)=bad/shuts down
agonist(dostinex)=good/works
with it
Sex Stuff:
"This study evaluated the effects of chronic treatment with cabergoline (CAB), a new, potent and long-lasting ergoline-derived dopamine agonist, on seminal fluid parameters and sexual and gonadal function in hyperprolactinemic males in comparison with the effect of bromocriptine (BRC) treatment. Seventeen males with macroprolactinoma (this is so much prolactin that it becomes a prolactin-secreting pituitary tumour which is more than 10mm (½ inch) in diameter) were treated with CAB at a dose of 0.5-1.5 mg/week, or BRC at a dose of 5-15 mg/day for 6 months. Baseline prolactin (PRL) was 925.7 +/- 522.6 microg/l in the CAB-treated group and 1059.4 +/- 297.6 microg/l in the BRC-treated group.
All the patients suffered from libido impairment, ten from reduced sexual potency, and six had infertility. In five patients provocative bilateral galactorrhea (fluid from your nipples) was found. Seminal fluid analysis, functional seminal tests and penis rigidity and tumescence, measured by nocturnal penile tumescence (NPT) using Rigiscan equipment, were assessed before and after 1, 3 and 6 months of CAB or BRC treatment. Hormone profiles were assessed before and after 15, 30, 60, 90 and 180 days of both treatments. Before treatment, all patients had a low sperm count with oligoasthenospermia, reduced motility and rapid progression with an abnormal morphology and decreased viability, and a low number of erections. After 1 month, serum PRL levels were significantly reduced in both groups of patients (20.6 +/- 6.6 microg/l during CAB and 256.3 +/- 115.1 microg/l during BRC treatment) and were normalized after 6 months in all patients (CAB: 7.9 +/- 2.2 microg/l; BRC: 16.7 +/- 1.8 microg/l). After 6 months, a significant increase of number, total motility, rapid progression and normal morphology was recorded in patients treated with both CAB and BRC. An increase in the number of erections during the first 3 months of both treatments was noted by NPT. However, the improvements in seminal fluid parameters and sexual function were more evident and rapid in patients treated with CAB. The number of erections was normalized after 6 months of treatment in all patients submitted to CAB treatment, and in all patients but one treated by BRC. In addition, a significant increase of serum testosterone (from 3.7 +/- 0.3 to 5.3 +/- 0.2 microg/l) and dihydrotestosterone (from 0.4 +/- 0.1 to 1.1 +/- 0.1 nmol/l) was recorded. At the beginning of treatment, mild side-effects were recorded in two patients after CAB and mild-to-moderate side-effects in five patients after BRC administration. The treatment with CAB normalized PRL levels, improving gonadal and sexual function and fertility in males with prolactinoma, earlier than did BRC treatment, providing good tolerability and excellent patient compliance to medical treatment."
Look at it this way, if it takes a few months for people with ridiculous amounts of prolactin and a prolactin geyser on their pituitary gland; it would only take weeks with supplemental use of Dostinex.